The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors
Open accessAbstract
Analyses of compounds in clinical development have shown that ligand efficient-molecules with privileged physical properties and low dose are less likely to fail in the various stages of clinical testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings. However, detailed side-by-side examination of molecular interactions and properties within single drug classes are lacking. As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis. Despite the clear role of the molecular target, member molecules of this validated drug class exhibit distinct clinical efficacy and safety profiles in comparable renal cell carcinoma clinical studies. The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clinical performance [Rini BI, et al. (2011) Lancet 378:193–1939]. To elucidate how fundamental drug potency–efficiency is achieved and impacts differentiation within the VEGFR TKI class, we determined potencies, time dependence, selectivities, and X-ray structures of the drug–kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain. Collectively, the studies elucidate unique drug–kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences. The identified structural trends are consistent with in vitro measurements, which translate well to clinical performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
X-PLOR Version 3.1: A System for X-ray Crystallography and NMR
Brünger, A. T. (1992) · Medical Entomology and Zoology · Cited by 3,424
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Data processing and analysis with the autoPROC toolbox
Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., & Bricogne, G. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911007773 · Cited by 2,029
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., Negrier, S., Chevreau, C., Desai, A. A., Rolland, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5511 · Cited by 1,085
Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors
Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 814
Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L., Scheibe, D. N., Snell, G. P., Zou, H., Sang, B.-C., & Wilson, K. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403319200 · Cited by 635
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
A visual protein crystallographic software system for X11/Xview
McRee, D. (1992) · Journal of Molecular Graphics · doi:10.1016/0263-7855(92)80022-6 · Cited by 548
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain
Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J., & Saxena, K. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00505-7 · Cited by 499
Gajiwala, K. S., Wu, J. C., Christensen, J., Deshmukh, G. D., Diehl, W., DiNitto, J. P., English, J. M., Greig, M. J., He, Y.-A., Jacques, S. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812413106 · Cited by 391
Self-citationThe Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388
Coppin, C., Kollmannsberger, C., Le, L., Porzsolt, F., & Wilt, T. J. (2011) · BJU International · doi:10.1111/j.1464-410x.2011.10629.x · Cited by 266
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Roodhart, J., Langenberg, M., Witteveen, E., & Voest, E. (2008) · Current Clinical Pharmacology · doi:10.2174/157488408784293705 · Cited by 204
McTigue, M. A., Wickersham, J. A., Pinko, C., Showalter, R. E., Parast, C. V., Tempczyk-Russell, A., Gehring, M. R., Mroczkowski, B., Kan, C.-C., Villafranca, J. E., et al. (1999) · Structure · doi:10.1016/s0969-2126(99)80042-2 · Cited by 203
Self-citationDiastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Rini, B. I., Schiller, J. H., Fruehauf, J. P., Cohen, E. E. W., Tarazi, J. C., Rosbrook, B., Bair, A. H., Ricart, A. D., Olszanski, A. J., Letrent, K. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2806 · Cited by 181
Physicochemical drug properties associated within vivotoxicological outcomes: a review
Price, D. A., Blagg, J., Jones, L. H., Greene, N., & Wager, T. T. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903042318 · Cited by 167
Edwards, M. P., & Price, D. A. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45023-x · Cited by 147
Wodicka, L. M., Ciceri, P., Davis, M. I., Hunt, J. P., Floyd, M. B., Salerno, S. N., Hua, X. H., Ford, J. M., Armstrong, R. C., Zarrinkar, P. P., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.09.010 · Cited by 134
Murphy, D. J. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2003.12.018 · Cited by 107
Reducing the Risk of Drug Attrition Associated with Physicochemical Properties
Leeson, P. D., & Empfield, J. R. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45024-1 · Cited by 85
The 2.7 Å Crystal Structure of the Autoinhibited Human c-Fms Kinase Domain
Walter, M., Lucet, I. S., Patel, O., Broughton, S. E., Bamert, R. S., Williams, N. K., Fantino, E., Wilks, A. F., & Rossjohn, J. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.01.036 · Cited by 81
Harmange, J.-C., Weiss, M. M., Germain, J., Polverino, A. J., Borg, G., BREADY, J. V., Chen, D., Choquette, D. M., Coxon, A., DeMelfi, T., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701097z · Cited by 80
Vascular Endothelial Growth Factor–Targeted Therapies in Advanced Renal Cell Carcinoma
Albiges, L. K., Salem, M. E., Rini, B. I., & Escudier, B. J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.04.006 · Cited by 62
Solowiej, J. E., Bergqvist, S., McTigue, M. A., Marrone, T. J., Quenzer, T. L., Cobbs, M., Ryan, K., Kania, R. S., Diehl, W. C., & Murray, B. W. (2009) · Biochemistry · doi:10.1021/bi900522y · Cited by 52
Self-citationHigh-Throughput Biochemical Kinase Selectivity Assays: Panel Development and Screening Applications
Card, A., Caldwell, C., Min, H., Lokchander, B., Xi, H. S., Sciabola, S., Kamath, A. V., Clugston, S. L., Tschantz, W. R., Wang, L., et al. (2008) · SLAS DISCOVERY · doi:10.1177/1087057108326663 · Cited by 51
Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.
Luca, A. D., & Normanno, N. (2010) · PubMed · Cited by 46
Lessons learned from candidate drug attrition.
Empfield, J. R., & Leeson, P. D. (2010) · PubMed · Cited by 40
Targeting the unactivated conformations of protein kinases for small molecule drug discovery
Alton, G., & Lunney, E. A. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.6.595 · Cited by 33
Cited by
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Jonasch, E., Gao, J., & Rathmell, W. K. (2014) · BMJ · doi:10.1136/bmj.g4797 · Cited by 636
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 636
Metadata
- Authors
- McTigue, M., Murray, B. W., Chen, J. H., Deng, Y.-L., Solowiej, J., & Kania, R. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-09-05
- Volume
- 109
- Issue
- 45
- Pages
- 18281-18289
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2063544208
- Cited by
- 592
- References
- 36
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.